

Supplementary Table 5. Annual incidence rates per 100,000 person-years for 8 adverse events of special interest in South Korea by age group based on broad definition

AESI type	Age (y)	2015	2016	2017	2018	2019
Acute myocarditis	0-19	1.86 (0.70-4.97)	3.82 (1.91-7.64)	2.97 (1.33-6.61)	2.04 (0.77-5.44)	3.17 (1.42-7.06)
	20-39	4.34 (1.95-9.66)	2.15 (0.69-6.65)	0.71 (0.10-5.05)	2.84 (1.07-7.58)	0.71 (0.10-5.05)
	30-64	1.42 (0.71-2.84)	2.64 (1.59-4.38)	1.77 (0.95-3.29)	2.47 (1.46-4.17)	2.65 (1.60-4.40)
	≥65	2.14 (0.69-6.63)	2.75 (1.03-7.34)	1.97 (0.63-6.10)	3.15 (1.31-7.58)	3.61 (1.62-8.04)
Acute pericarditis	0-19	1.40 (0.45-4.34)	1.43 (0.46-4.44)	1.98 (0.74-5.27)	2.55 (1.06-6.14)	4.23 (2.11-8.45)
	20-39	6.51 (3.39-12.52)	2.86 (1.07-7.62)	4.27 (1.92-9.50)	2.13 (0.69-6.61)	4.26 (1.92-9.49)
	30-64	8.17 (6.12-10.91)	5.29 (3.70-7.56)	7.60 (5.64-10.25)	7.59 (5.63-10.23)	6.89 (5.04-9.44)
	≥65	18.53 (12.62-27.22)	19.28 (13.31-27.92)	22.30 (15.94-31.21)	22.72 (16.39-31.49)	26.50 (19.72-35.61)
Acute disseminated encephalomyelitis	0-19	1.40 (0.45-4.34)	0.48 (0.07-3.39)	2.47 (1.03-5.94)	1.02 (0.26-4.08)	2.64 (1.10-6.35)
	20-39	-	-	-	-	-
	30-64	0.36 (0.09-1.42)	0.18 (0.02-1.25)	-	-	0.53 (0.17-1.64)
	≥65	-	-	0.66 (0.09-4.66)	-	-
Acute transverse myelitis	0-19	0.93 (0.23-3.73)	0.48 (0.07-3.39)	0.49 (0.07-3.51)	0.51 (0.07-3.63)	0.53 (0.07-3.75)
	20-39	1.45 (0.36-5.79)	1.43 (0.36-5.72)	0.71 (0.10-5.05)	2.13 (0.69-6.61)	0.71 (0.10-5.05)
	30-64	2.84 (1.74-4.64)	2.82 (1.73-4.60)	2.30 (1.33-3.96)	3.35 (2.14-5.26)	3.01 (1.87-4.83)
	≥65	5.70 (2.85-11.40)	2.75 (1.03-7.34)	3.93 (1.77-8.76)	3.79 (1.70-8.43)	3.61 (1.62-8.04)
Encephalitis	0-19	12.59 (8.63-18.36)	11.95 (8.07-17.68)	13.85 (9.57-20.07)	8.17 (5.01-13.34)	13.21 (8.93-19.56)
	20-39	6.51 (3.39-12.52)	7.87 (4.36-14.20)	4.98 (2.37-10.44)	7.11 (3.82-13.21)	7.82 (4.33-14.12)
	30-64	9.94 (7.65-12.92)	7.58 (5.62-10.22)	10.43 (8.08-13.47)	8.83 (6.69-11.65)	8.84 (6.70-11.66)
	≥65	15.68 (10.32-23.81)	13.77 (8.88-21.34)	15.09 (10.02-22.70)	17.03 (11.68-24.84)	18.07 (12.63-25.84)
Anaphylaxis	0-19	38.23 (30.79-47.47)	33.93 (26.89-42.82)	44.04 (35.78-54.21)	45.97 (37.39-56.52)	45.46 (36.80-56.16)
	20-39	29.67 (21.85-40.29)	30.75 (22.80-41.46)	32.71 (24.50-43.67)	35.55 (26.94-46.90)	45.49 (35.61-58.12)
	30-64	44.22 (39.06-50.07)	47.23 (41.90-53.24)	57.30 (51.39-63.89)	58.44 (52.47-65.08)	63.13 (56.91-70.03)
	≥65	42.76 (33.20-55.07)	50.95 (40.57-63.98)	56.41 (45.66-69.69)	63.73 (52.44-77.45)	72.88 (60.98-87.09)
Bell's palsy	0-19	25.18 (19.28-32.88)	28.20 (21.85-36.39)	29.69 (23.05-38.24)	25.03 (18.92-33.12)	17.97 (12.84-25.15)
	20-39	63.71 (51.70-78.52)	70.83 (58.16-86.25)	63.31 (51.44-77.94)	68.99 (56.54-84.18)	58.31 (46.96-72.40)
	30-64	131.20 (122.06-141.01)	145.74 (136.14-156.03)	149.45 (139.70-159.88)	144.06 (134.50-154.30)	160.04 (149.94-170.82)
	≥65	223.53 (200.09-249.71)	258.02 (233.15-285.54)	255.78 (231.59-282.51)	256.13 (232.36-282.33)	266.22 (242.50-292.26)
Lymphadenitis	0-19	2,617.40 (2,548.51-2,688.15)	2,585.18 (2,515.95-2,656.32)	2,515.78 (2,446.32-2,587.21)	2,578.06 (2,506.63-2,651.51)	2,572.32 (2,499.75-2,647.00)
	20-39	2,028.31 (1,953.47-2,106.01)	2,042.45 (1,967.82-2,119.92)	2,279.52 (2,200.77-2,361.08)	2,291.74 (2,212.69-2,373.61)	2,439.79 (2,358.16-2,524.25)
	30-64	1,767.62 (1,732.76-1,803.17)	1,879.18 (1,843.38-1,915.68)	1,892.32 (1,856.31-1,929.02)	2,040.81 (2,003.42-2,078.91)	2,130.55 (2,092.28-2,169.52)
	≥65	1,596.47 (1,530.94-1,664.80)	1,622.25 (1,557.30-1,689.90)	1,709.09 (1,643.93-1,776.82)	1,878.90 (1,811.76-1,948.54)	2,048.69 (1,980.03-2,119.73)

AESI, adverse events of special interest.

Incidence rates were expressed per 100,000 person-years with 95% confidence interval.